Drugs / GPC-100
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05561751 | Feb 2023 → Sep 2025 | plasma cell myeloma | GPCR Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GPC-100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05561751 ↗ |
| Known as | Burixafor | “All patients will receive via IV 3.14 mg/kg GPC-100 (Burixafor) at least 2 hours prior to leukapheresis sessions” NCT05561751 ↗ |
| Action | Inhibit | “GPC-100, a small molecule antagonist of CXCR4” PMID 37878624 ↗ Oct 2023 |
| Modality | Small molecule | “GPC-100, a small molecule antagonist of CXCR4” PMID 37878624 ↗ Oct 2023 |
| Route | Intravenous | “via IV infusion” NCT05561751 ↗ |
| Target | CXCR4 | “GPC-100, a small molecule antagonist of CXCR4” PMID 37878624 ↗ Oct 2023 |